Grants FY23-24

“Singapore Primary Angle Closure Evaluation and Diagnostics (SPACED) Study”
Assoc Prof Monisha Esther Nongpiur; S$675,00.00

“Explainable Artificial Intelligence for Glaucoma Detection”
Assoc Prof Jacqueline Chua; S$675,00.00

“Transforming Population Eye Health Research (Transformer) Program: From Data and Algorithms to Precision Health”
Prof Cheng Ching-Yu; S$1,750,000.00

“Diabetes studY in Nephropathy and Other Microvascular cOmplications II”
Assoc Prof Gavin Tan; S$3,934,317.19

“Detection and Optimization of Treatment of Severe Cases of Dry Eye Disease”
Prof Louis Tong; S$1,342,686.16

“The Role of Primary Angle-Closure Glaucoma (PACG) Susceptibility Gene, EPDR1 in Clinical PACG Severity and Intraocular Pressure Susceptibility”
Dr Anita Chan; S$675,000.00

“Targeting Novel Macular Pigment Analysis and Therapy to Improve Vision-Related and Patient-Centred Outcomes for Epiretinal Membrane Surgery”
Assoc Prof Danny Cheung Ning; S$674,584.44

“A Bioinspired and Photoprotective Scaffold for Retinal Stem Cell Therapy.”
Assoc Prof Amutha Barathi; S$250,000.00

“Bioengineered Corneal Endothelial Graft Using Photo-Dissolvable Biomaterial to Induce Graft-Host Integration”
Prof Jodhbir S Mehta; S$510,043.30

“Implementation of Fast, Precise, and Novel Eye-Specific, Quality of Life Computerized Adaptive Tests (Cats) in Tertiary Eye Clinics Across Singapore”
Prof Ecosse Lamoureux; S$562,060.00

“Biological Mechanisms of the Protective Effecto Statin Medication for the Treatment of Age-Related Macular Degeneration (AMD)”
Dr Simon Nusinovici; S$145,000.00

“Evaluation of the Safety of Terahertz Scanning System on Corneas: Phase I Trial”
Dr Liu Chang; S$49,840.00

“A Novel Pre-Adapted Bacteriophage Therapy for Methicillin Resistant Staphylococcus Aureus (MRSA) Infections”
Dr Thet Tun Aung; S$49,967.00

“A Model for Myopic Traction Maculopathy Based on Retinal Biomechanics”
Assoc Prof Donny Hoang; S$125,000.00

“Singapore Epidemiology Of Eye Diseases Cohort (SEED): Building a Technology-Driven Platform to Facilitate Data Sharing and Analytics”
Prof Cheng Ching-Yu; S$480,000.00

“THEA – Terahertz High Definition Eye Analysis”
Assoc Prof Liu Yu-Chi; S$700,000.00

“Novel Therapeutic Molecule for the Treatment of Ocular Angiogenic Diseases”
Dr Danny Belkin, Assoc Prof Wang Xiaomeng; S$15,000

“XFG New Target: Phase IIb In-vitro Mechanistic Analysis”
Prof Aung Tin; S$362,954.63

“Targeting Hypoxia-Inducible Factors (HIF) for the Treatment of Ocular Neovascularization”
Assoc Prof Gavin Tan; MSD$257,834

“A Phase III, Multicenter, Randomized, Double-masked, Sham-controlled Study to Investigate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ro7200220 Administered Intravitreally in Patients with Uveitic Macular Edema-Sandcat”
Dr Anita Chan; S$65,189.93

“A Post-Authorization, Multicenter, Multinational, Longitudinal, Observational Safety Registry Study for Patients Treated with Voretigene Neparvovec”
Dr Chan Choi Mun; S$18,831.93

“A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Choroidal Neovascularization Secondary to Pathological Myopia (POYANG)”
Prof Gemmy Cheung; S$102,690.94

“A Phase III, Randomized, Double-masked, Placebo-controlled, Multicenter Study to evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants with Moderate to Severe Thyroid Eye Disease”
Clin Assoc Prof Sunny Shen; S$99,525.29

“Real-world, Long-term, Data Collection to Gain Clinical Insights Into Roche Ophthalmology products (Voyager study)”
Assoc Prof Kelvin Teo; S$66,300.00

“A Phase IIIb, Global, Multicenter, Randomized, Visual Assessor-Masked Study of the Efficacy, Safety, And Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System with Ranibizumb in Patients with Neovascular Age-Related Macular Degeneration (Velodrome)”
Prof Gemmy Cheung; S$168,766.08